OptiMAL Library video
Fusion Antibodies plc has released a video detailing its Opti-library of antibody sequences, a technology protected by US patent no. 17/287,441, which has been integrated into the OptiMAL® library for discovering novel human antibodies. This OptiMAL® library is scheduled for commercial launch in December 2025, and the video is available on the Company's investor hub to provide shareholders with further insight into its technological platforms and service offerings.
Select text to share a quote on X · sign in to keep highlights & notes in your FAB notes
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has prepared a short video of Dr Richard Buick, CSO, explaining some of the features, science and technology behind the Company's Opti-library of antibody sequences.
The Opti-library design and method is protected by US patent no. 17/287,441. It has been combined with Fusion's mammalian display platform to create the OptiMAL® library, and it intended to be used to discover novel human antibodies against any target. OptiMAL® is due for commercial launch in December 2025.
The video can be viewed on the Investor Hub section of Fusion's website at, https://investorhub.fusionantibodies.com/s/7ea305.
This video is the latest in a series of videos providing shareholders and investors with more information on the Company's technological platforms and service offerings. These videos can be found here https://investorhub.fusionantibodies.com/s/1b6535.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.